Stock Track | Telix Pharmaceuticals Soars 9.62% Intraday on Strong Pipeline and Commercial Imaging Revenue

Stock Track

Jun 24

Telix Pharmaceuticals Ltd (ASX:TLX) saw its stock price surge 9.62% during intraday trading on Wednesday.

The company, which develops radiopharmaceutical imaging agents and therapies for cancers, is generating significant revenue from its commercial Precision Medicine segment, with products like Illuccix and Gozellix in use across major markets. Investors appear optimistic about its late-stage therapy pipeline, including Phase 3 programs TLX591 and TLX101-Tx, which target long-term treatment revenue.

Further positive sentiment may stem from the company's collaborations with partners like Regeneron and United Imaging, as well as its current valuation trading on lower price-to-sales multiples compared to many Australian biotech peers, presenting a potential value opportunity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1120285849"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120285849\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120285849?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 10:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120285849","market":"nz","top_or_hot":-1,"title":"Stock Track | Telix Pharmaceuticals Soars 9.62% Intraday on Strong Pipeline and Commercial Imaging Revenue","media":"Stock Track","content":"<p>Telix Pharmaceuticals Ltd (ASX:TLX) saw its stock price surge 9.62% during intraday trading on Wednesday.</p><p>The company, which develops radiopharmaceutical imaging agents and therapies for cancers, is generating significant revenue from its commercial Precision Medicine segment, with products like Illuccix and Gozellix in use across major markets. Investors appear optimistic about its late-stage therapy pipeline, including Phase 3 programs TLX591 and TLX101-Tx, which target long-term treatment revenue.</p><p>Further positive sentiment may stem from the company's collaborations with partners like Regeneron and United Imaging, as well as its current valuation trading on lower price-to-sales multiples compared to many Australian biotech peers, presenting a potential value opportunity.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Telix Pharmaceuticals Soars 9.62% Intraday on Strong Pipeline and Commercial Imaging Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Telix Pharmaceuticals Soars 9.62% Intraday on Strong Pipeline and Commercial Imaging Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-24 10:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Telix Pharmaceuticals Ltd (ASX:TLX) saw its stock price surge 9.62% during intraday trading on Wednesday.</p><p>The company, which develops radiopharmaceutical imaging agents and therapies for cancers, is generating significant revenue from its commercial Precision Medicine segment, with products like Illuccix and Gozellix in use across major markets. Investors appear optimistic about its late-stage therapy pipeline, including Phase 3 programs TLX591 and TLX101-Tx, which target long-term treatment revenue.</p><p>Further positive sentiment may stem from the company's collaborations with partners like Regeneron and United Imaging, as well as its current valuation trading on lower price-to-sales multiples compared to many Australian biotech peers, presenting a potential value opportunity.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX.AU","symbol_name":"TELIX PHARMACEUTICALS LTD","start_time":0,"source_url":"","article_id":"1120285849","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120285849","pubTimestamp":1782269074,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Telix Pharmaceuticals Ltd (ASX:TLX) saw its stock price surge 9.62% during intraday trading on Wednesday.The company, which develops radiopharmaceutical imaging agents and therapies for cancers, is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"个股赛道|Telix Pharmaceuticals盘中飙升9.62%，得益于强劲的管线和商业影像收入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":1},"content_text":"Telix Pharmaceuticals Ltd (ASX:TLX) saw its stock price surge 9.62% during intraday trading on Wednesday.The company, which develops radiopharmaceutical imaging agents and therapies for cancers, is generating significant revenue from its commercial Precision Medicine segment, with products like Illuccix and Gozellix in use across major markets. Investors appear optimistic about its late-stage therapy pipeline, including Phase 3 programs TLX591 and TLX101-Tx, which target long-term treatment revenue.Further positive sentiment may stem from the company's collaborations with partners like Regeneron and United Imaging, as well as its current valuation trading on lower price-to-sales multiples compared to many Australian biotech peers, presenting a potential value opportunity.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}